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Abstract
Background: The transition from adolescence to adulthood is associated with the emergence of psychosis and
other mental health problems, highlighting the importance of this developmental period for the understanding
of developing psychopathology and individual differences in risk and resilience. The Youth Mental Health Risk and
Resilience Study (YouR-Study) aims to identify neurobiological mechanisms and predictors of psychosis-risk with a
state-of-the-art neuroimaging approach (Magnetoencephalography, Magnetic Resonance Spectroscopy, Magnetic
Resonance Imaging) in combination with core psychological processes, such as affect regulation and attachment,
that have been implicated in the development and maintenance of severe mental health problems.
Methods/Design: One hundred participants meeting clinical high-risk criteria (CHR) for psychosis through the
Comprehensive Assessment of At-Risk Mental State and Schizophrenia Proneness Instrument, Adult Version, in
the age range from 16 to 35 years of age will be recruited. Mental-state monitoring up to a total of 2 years will
be implemented to detect transition to psychosis. In addition, a sample of n = 40 help-seeking participants will
be recruited who do not meet CHR-criteria, a group of n = 50 healthy control participants and a sample
of n = 25 patients with first-episode psychosis. MEG-activity will be obtained during auditory and visual tasks
to examine neural oscillations and event-related fields. In addition, we will obtain estimates of GABA and
Glutamate levels through Magnetic Resonance Spectroscopy (MRS) to examine relationships between neural
synchrony and excitatory-inhibition (E/I) balance parameters. Neuroimaging will be complemented by detailed
neuropsychological assessments as well as psychological measures investigating the impact of childhood
abuse, attachment experiences and affect regulation.
Discussion: The YouR-study could potentially provide important insights into the neurobiological mechanisms
that confer risk for psychosis as well as biomarkers for early diagnosis of severe mental health problems.
Moreover, we expect novel data related to the contribution of affect regulation and attachment-processes
in the development of mental health problems, leading to an integrative model of early stage psychosis and
the factors underlying risk and resilience of emerging psychopathology.
Keywords: Adolescence, Psychosis, Early intervention, Biomarker, Affect regulation, Attachment
Background
The transition from adolescence to adulthood is associ-
ated with frequent mental health problems, ranging
from affective disorders to more severe forms of psycho-
pathology, such as psychosis [1]. Current data suggests
that approximately one in every four to five youth will
develop a mental disorder with severe impairment across
their lifetime [2]. Accordingly, understanding the devel-
opmental trajectory as well as potential ways to identify
early signs of serious mental health problems is a key
priority of current research [3].
Among mental health problems with an onset during
the transition from adolescence to adulthood, psychotic
disorders, such as those labelled as schizophrenia (ScZ),
are a particular challenge given that certain cognitive
and physiological signals are already present prior to the
manifestation of psychosis [4]. Because the actual onset
of psychotic symptoms is frequently accompanied by an
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extended prodromal phase of up to 5–6 years [5], clinical
high-risk criteria (CHR) have been developed that allow
the identification of young people at risk of developing
psychoses. Firstly, Ultra-high risk (UHR) criteria are based
on the presence of attenuated, psychotic symptoms as
assessed by the Comprehensive Assessment of At-Risk
Mental State (CAARMS) instrument [6] or the Structured
Interview for Prodromal Symptoms (SIPS) [7]. Moreover,
UHR-criteria on the CAARMS and SIPS instruments in-
clude a genetic risk and deterioration syndrome as well as
brief limited intermittent psychotic episodes (BLIPs).
Secondly, CHR have been developed based on the
basic symptom (BS) concept proposed by Huber and
colleagues [8]. From this perspective, self-experienced
perceptual and cognitive anomalies represent the earliest
manifestation of psychosis risk while psychotic symp-
toms are considered as an adaptive response to render
the anomalous cognitive experiences coherent [8]. Re-
cent data from several studies using the Schizophrenia
Proneness Instrument, Adult Version (SPI-A), have
shown that CHR-criteria based on BS alone can identify
young people at-risk for the development of psychosis
with transition rates of up to 54.9% within four years
period [9]. Similar transition rates have been originally
observed for UHR-criteria, although recent studies have
indicated that transition rates may be decreasing, ran-
ging between 10 and 30% [4]. Interestingly, the combin-
ation of both basic symptoms and UHR-criteria the
predictive power [10].
While screening procedures are characterized by suffi-
cient diagnostic accuracy to detect at-risk individuals
[11], these approaches are currently not sensitive and
specific enough to predict psychosis-risk on an individ-
ual level, a key objective for early intervention research.
Accordingly, biomarkers may be required to boost pre-
diction and furthermore to allow insights into the under-
lying neurobiology of the at-risk state. The search for
underlying mechanisms und biomarkers is furthermore
complicated by the fact that CHR-participants are a
highly heterogeneous phenotype with genetic and envir-
onmental risk factors contributing to the at-risk state for
psychosis, including trauma and affect dysregulation
[12]. This is highlighted by recent findings that CHR-
participants who do not convert to psychosis develop a
range of psychiatric disorders, including affective and
personality disorders [13]. Accordingly, the CHR-state
may not only confer risk for the development of psych-
osis per se but more broadly for diverse psychopathology
[14].
Rationale
While data from neuroimaging and neurophysiology
have demonstrated that many of the patterns observed
in ScZ-patients are already present in at-risk individuals
[4], the underlying neurobiological and psychological
mechanisms that give rise to subthreshold psychotic
symptoms and self-experienced cognitive and perceptual
disturbances remain poorly understood.
The search for biomarkers for early diagnosis and
prognosis in CHR-participants has been largely
conducted with anatomical and functional Magnetic
Resonance Imaging (MRI/fMRI), brain imaging tech-
niques with excellent spatial resolution. While useful
in delineating the architecture of functional and ana-
tomical networks, these techniques only allow only
indirect links to cellular and physiological mecha-
nisms of circuit abnormalities [15]. Moreover, MRI
approaches are unable to capture neural processes
with high temporal resolution, which is essential for
measuring fast rhythmic fluctuations of neuronal
events that have been recently implicated in major
psychiatric conditions [16].
Accordingly, the development of biomarkers may
require a stronger focus on non-invasive techniques
that allow a direct assessment of neuronal dynamics
at high temporal resolution. This approach is sup-
ported by emerging evidence suggests that ScZ is as-
sociated with specific impairments in neural
oscillations and their synchronization (neural syn-
chrony), in particular at gamma-band frequencies
(30–200 Hz) [15]. Brain oscillations have been shown
to occur during normal brain functioning and are
closely linked to the ability to perceive, memorize and
attend to information [17–19]. Thus, it appears that
brain oscillations could be a key to understanding the
neurobiological mechanisms of psychosis-risk as well
as provide biomarkers for predicting mental health
outcomes, including psychosis, in CHR-individuals.
Importantly, the impairments in neural synchrony are
ideally suited for translational research because of evi-
dence linking gamma-band oscillations during normal
brain functioning to the integrity of GABAergic inter-
neurons [20] and glutamatergic neurotransmission
[21]. Supporting this hypothesis, the diagnosis of ScZ
is associated with pronounced abnormalities in levels
of GABA and Glutamate measured by magnetic res-
onance spectroscopy (MRS) [22]. Finally, blood and
urine-samples will be collected to allow for potential
genetic testing and proteomic analysis.
In addition to basic insights into the neurobiology of
circuit dysfunction conferring risk for psychosis, the
YouR-study will examine several core psychological pro-
cesses involved in the maintenance and development of
psychosis and several mental health problems, such as
affectregulation and attachment. Evidence from behav-
ioural and neuroimaging-studies suggests that problems
in affect regulation may constitute a core risk factor in
ScZ [23] which could be related to early trauma [24].
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Preliminary evidence suggests that CHR-participants
may experience greater difficulties in affect regulation
[25] but the relationship to early trauma is unclear.
Accordingly, we will further explore the role of affect
regulation in at-risk participants and its relationship to
psychosis as well as the role of attachment styles in the
developmental trajectory of CHR-participants and its
relationship to clinical variables.
Aims
The primary aim of the YouR-study is to characterize
changes in neural oscillations in CHR-participants and
to develop a biomarker for psychosis-prediction and
mental health outcomes. Accordingly, we will recruit a
sample of n = 100 CHR-individuals for psychosis and
apply MEG during cognitive tasks and resting-state ac-
tivity in combination with advanced analytic tools to
identify the frequencies as well as brain regions involved
in aberrant neural synchrony. In addition, to establish
links between neural synchrony and E/I-balance parame-
ters MRS-measured GABA/Glutamate levels in auditory
and visual cortices will be obtained. During a follow-up
period of up to two years, transition to psychosis, func-
tional status and changes in affect-regulation will be
monitored. Moreover, the study will identify the rela-
tionship between disturbances in affect regulation, at-
tachment and trauma and their contribution towards the
development of psychosis.
Methods/Design
The study will be a longitudinal cohort design with
CHR-participants using neuroimaging to investigate
brain activity and psychological measures to identify risk
and resilience factors as well as biomarkers for emerging
mental health problems. The YouR-Study will be
performed according to the Research Governance
Framework for Health and Community Care (Second
edition, 2006).
Recruitment and participants
We aim to recruit up to n = 100 participants meeting
CHR-criteria in the age range from 16–35 years and we
expect to identify from this participant group an add-
itional n = 25 participants who meet criteria for FEP over
a four-year period. The recruitment of the CHR- and
FEP-groups will involve NHS-patients services in NHS
Greater Glasgow and Clyde and NHS Lothian, NHS First
Episode Psychosis Services, Community Mental Health
Teams (CMHTs), Primary Care Mental Health Teams
(PCMHTs), Clinical Psychology Services, Community
Adolescent Mental Health Services (CAMHS), and Non-
Governmental mental health organisations. Recruitment
for the YouR-study began in October 2014 and is
expected to continue until 12/2017.
In addition, the YouR-study recruits from the general
population through a website http://www.your-study.
org.uk which includes an initial screening through the
16-item version of the prodromal questionnaire (PQ)
[26] and a 12-item scale of perceptual and cognitive
items. Previous data suggested that a cut-off score of 6
or more positively answered items on the 16-item
version of the PQ produced correct classification of
CHR-criteria based on CAARMS-interviews with high
sensitivity and specificity [26].
CHR- and FEP-groups will be compared to two groups
of participants: 1) A group of n = 40 help-seeking partici-
pants below the threshold for UHR- or SPI-A criteria
who will be recruited through the same recruitment
pathways as participants meeting CHR-criteria (low-
risk group). The reason for the inclusion of this
group is to control for non-specific factors associated
with CHR-individuals, such as the presence of co-morbid
non-psychotic psychopathology, drug abuse and lower
educational status. And 2) A group of n = 50 participants
without the presence of any current DSM-IV disorder,
current substance abuse and first-degree relative with
psychosis.
Clinical-assessments and CHR-criteria
To establish CHR-criteria, the CAARMS-Interview [15,
16] and the COGDIS/COPER items for the SPI-A [27]
are administered. Participants are recruited into the
CHR-group if they meet a) SPI-A COGDIS/COPER-cri-
teria b) ARMS attenuated psychosis group (subthreshold
psychotic syndrome present in the last year without a
decline in functioning) c) ARMS vulnerability group
(family history of psychosis plus a 30% drop in GAF)
and d) ARMS BLIPs-group (brief limited intermittent
psychotic symptoms). In addition, the M.I.N.I. Inter-
national Neuropsychiatric Interview (M.I.N.I. 6.0) [28]
will be administered to identify psychiatric comorbid-
ity as well as the scales for premorbid adjustment
[29] and social and functional role scale will be
administered [30]. Previous studies indicated that
these variables are significantly impaired in CHR-
participants and are predictors for transition to psych-
osis and functional outcome [31–33].
Neuropsychology
CHR-participants are characterized by cognitive defi-
cits in several domains, including processing speed
and verbal memory [34], which are predictors for
transition to psychosis [35]. The neuropsychological
assessment of the YouR-study consists of the Brief
Assessment of Cognition in Schizophrenia Battery
(BACS) which has been extensively used in ScZ-
research [36]. In addition, the following tasks from
the University of Pennsylvania Computerized
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Neuropsychological Testing Battery (PennCNP [37]: a)
Continuous Performance Test b) N-Back Task and c)
Emotion Identification Task will be included in the
neuropsychological assessment. Finally, the Edinburgh
Handedness Inventory [38] and the National Adult
Reading Test [39] will be administered.
Questionnaires
Several psychological measures will be used in order to
identify mechanisms of change and predictors of transi-
tion to psychosis and outcome. All are brief self-report
scales, which have good psychometric properties. These
include: 1) The Beliefs About Paranoia Scale (BAPS)
[40] 2) The Brief Core Schema Scale (BCSS) [41] 3) The
Psychosis Attachment Measure (PAM-SR) [42] 4) Ad-
verse childhood experience scale (ACES) [43] and 5)
The Rust Inventory of Schizotypal Cognitions (RISC)
[44] 6) Inventory of interpersonal problems [45]– 32
item Version 7) The Significant Others Scale [46] and 8)
The International Positive and Negative Affect Schedule,
short-form (I-PANAS-SF) [47] and 9) Social Interaction
Anxiety Scale [48] and the Functional Remission in
General Schizophrenia (FROGS) scale [49].
Follow-up
Follow-up interviews will be conducted every 3–6
months with CHR and low-risk participants. This will
include subscales of the CAARMS as well as question-
naires to examine stress-levels, interpersonal functioning
and affect regulation. In addition, the SCID I interview
and the social and functional role scales will be added at
follow-up appointments at 6, 12 and 24 months.
Outcome parameters
In addition to conversion to psychosis in CHR-
individuals, the YouR-study will examine changes in
global functioning as well as role and social function-




All neuroimaging experiments will be conducted within
the facilities of the Centre for Cognitive Neuroimaging
(CCNi), University of Glasgow. MEG-data will be re-
corded with a whole-head 248-channel 4D Neuroimag-
ing WH3600 system at 1017.25 Hz sampling-rate and
filtered with an online 400 Hz low-pass filter (DC-
400 Hz).
MEG signals will be pre-processed and analyzed using
the open source matlab-toolbox fieldtrip [50] and cus-
tomized scripts. Data-analyses will be conducted at sen-
sor and source-level in the 1–150 Hz frequency range.
Time-frequency representations will be estimated
through Morlet-Wavelets and Multi-tapers. In addition,
event-related fields (ERFs) during auditory mismatch
negativity (MMNm) and sensory attenuation will be
examined. MEG is ideally suited for the analysis of
source-activity and source-reconstruction techniques,
such as beamformers [51], and Minimum Norm
Estimates (MNE) will be employed [52].
We will employ individual head models using a com-
mon dipole grid in MNI space. Cortical segmentation
and surface reconstruction are performed using SPM8
as well as spatial alignment of structural MRIs. In a sec-
ond step, we will select peak voxels for the reconstruc-
tion of virtual channels which will allow the examination
of the time course of oscillatory activity within a speci-
fied frequency band and the analysis of functional con-
nectivity with measures such as Partial Directed
Coherence (PDC) [53], Granger Causality [54] and
Phase-Lagged Synchronization [55].
Experimental tasks
Resting-state measurement: We will obtain resting-state
data in an eyes-open condition (duration: 4 min) which
provides important evidence on the organization of
large-scale networks and their impairments.
Visual Grating Task: We will employ a visual task
that was designed to elicit robust high-frequency ac-
tivity in the context of focused attention [56]. On
each trial, participants are shown a circular sine wave
grating at central screen fixation that contracts to-
wards the fixation point. Participants are required to
press the response button with their right index fin-
ger when the stimulus increases in velocity which oc-
curs between 750 and 3000 ms post stimulus onset
(10% of the trials are catch trials in which no acceler-
ation occurred). Extensive evidence suggests that
high-frequency oscillations are robustly elicited by this
paradigm with a signal-increase at the source-level of
~200% and excellent test-retest reliability in controls
measured with MEG-data [57]. Moreover, data in
healthy controls [58] and invasive electrophysiological
data [59] suggest tight correlations of gamma-band
fluctuation with reaction times (RTs) RTs as well as
with detection rates in ScZ-patients [60].
An auditory steady-state (ASS) paradigm: Kwon et al.
[61] conducted the first 40 Hz ASSR-study in ScZ-
patients using EEG and reported reduced power and
synchronization to 40 Hz stimulation. These initial find-
ings have been replicated by several groups in EEG- and
MEG-recordings (for a review see [62]). Participants are
presented auditory stimuli consisting of 2000-msec
1000 Hz carrier tones, amplitude modulated at 40 Hz
(100 trials). In addition to the passive presentation of
ASS-stimuli, participants will be asked to initiate the
same auditory stimuli through button press which allows
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for a comparison between auditory responses during a
self-initiated sensory processing vs. passive stimulation
or (sensory attenuation) [63]. Evidence suggests that
both ScZ-patients as well as CHR-individuals are
impaired in sensory attenuation [64].
Auditory MMNm Paradigm: MMN is an event-related
potential/field elicited automatically by violations of
previously established auditory regularities [65]. MMN
amplitudes have been consistently found to be attenu-
ated in both medicated and unmedicated ScZ- patients
[66] Moreover, recent studies have found MMN signals
to be present already in CHR-participants, indicating
that MMN-deficits could represent a biomarker for
psychosis development [67].
The YouR MEG-battery will investigate MMNm amp-
litude responses to both duration deviants and sound
omissions during an auditory oddball paradigm in which
three different sequences of auditory stimuli will be pre-
sented binaurally at ~ 70 dB (150 ms SOA, 700–1000 ms
ISI). In addition, an omission sequence which contains
only four identical tones is included to examine auditory
predictions. Participants are instructed to focus their at-
tention away from the sounds and to perform a simple
visual detection task.
MRS-spectroscopy
We will examine both GABA and Glutamate/Glutamine
(Glx) levels with 1H-MRS in three 2 × 2 × 2 cm3 single-
volume ROIs 1) right visual cortex and 2) left and right
auditory cortex to examine correlations between fluctua-
tions in neural oscillations GABA/Glutamate levels. 1H-
MRS spectra will be acquired on a 3 T Siemens Magne-
tom Tim Trio MRI Scanner, using a 32-channel radio-
frequency head coil and a MEGA point-resolved
spectroscopy (PRESS) spectral J-difference editing se-
quence. The following parameters will be used: TR/TE
1500/68 ms, 1200 Hz acquisition bandwidth, vector size
of 512, 256 averages (128 editing-on and 128 editing-off
scan) and a delta frequency of −1.7 (on scan; special
symmetrical editing approach to remove contamination
of co-edited macromolecules at 1.9 ppm) and 7.5 ppm
(off scan).
To assess glutamate levels, both physiologically ac-
tive and inactive glutamate are measured (Glu). The
proposed sequence (MEGA-PRESS) allows the detec-
tion of an aggregated signal representing the sum of
glutamate and glutamine (Glx). Because the majority
of physiologically active glutamate is derived from
glutamine, high levels of Glx suggest elevated gluta-
matergic activity. We expect reduced GABA-levels
but elevated Glx levels in the CHR-group which
correlate with reduced power and peak-frequency of
γ-band activity.
Anatomical imaging: MRI/DTI
T1 weighted anatomical data will be acquired using a 3D
MPRAGE sequence (FoV = 256x256x176 mm3, voxel
size = 1x1x1 mm3, TR = 2250 ms, TE = 2.6 ms, TI =
900 ms, FA = 9°). For the analysis of MRI, we will focus
on measures of cortical thickness as well as volume of
gray and white matter. In addition to whole brain ana-
lyses, we will focus on ROIs in the auditory and visual
cortex to correlate alterations in structural variables with
MEG-parameters.
Moreover, the YouR-study will acquire DTI-data with
the following sequence: 2D slice selective spin echo EPI
sequence with diffusion encoding, 89 axial slices with a
thickness of 1.7 mm, TR/TE = 1200 ms/100 ms, band-
width = 1346 Hz/pixel, echo spacing = 0.85 ms. For DTI
analysis, 67 diffusion encoding directions with a b-value
of 1000 s/mm2 will be covered.
Sample size and power calculation
Our current research with MEG has demonstrated large
effect sizes for deficits in high-frequency oscillations in
chronically medicated ScZ-patients as well as in
medication-naïve FE-ScZ patients (chronic ScZ: d = 1.26;
FE-ScZ d = 1.0) [68, 69]. Because we will employ novel
and more advanced analyses approaches for the proposed
project, we are confident that we will maximise the possi-
bility to detect dysfunctions in CHR-participants that will
be in the range and above of effect sizes currently available
for prodromal ScZ-research.
Previous studies with a variety of methods, such as
MRI, fMRI as well as event-related potentials (ERPs),
have demonstrated anatomical and physiological impair-
ments in CHR-cohorts with medium to large effect sizes
compared [70]. Electrophysiological parameters were
among those deficits with the largest effects [67]. For ex-
ample, Atkinson et al. [71] demonstrated an impairment
in MMN in CHR-participants vs. controls of d = .75. Ac-
cordingly, given a sample of n = 50 controls and 100
CHR-participants and an estimated effect size of .75 for
the current study, the power to detect significant differ-
ences in MEG-parameters between controls and CHR-
participants is 97%.
In regards to the ability to distinguish between CHR-
participants who will transition to psychosis vs. CHR-
participants without conversions, previous published ef-
fect sizes have reported medium but also large effect
sizes for differences on anatomical and functional
parameters [70]. For the current study, a conservative,
medium effect-size of d = .50 for a sample of n = 30 con-
verted CHR-participants vs. 70 CHR-non converted
CHR-participants will yield a statistical power to detect
significant differences between converted vs. non-
converted CHR-participants of 82%. The sample of n =
30 converted CHR-participants is consistent with a
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meta-analysis on conversion rates in CHR-participants
over a two year period [4]. Should CHR-participants be
lost in the follow-up period, we will recruit additional
participants during the course of the project.
Statistical analysis
Interim analysis of neuroimaging and clinical data will
be carried out after the recruitment of n = 50 CHR,
25 low-risk and 25 control participants. We will sys-
tematically explore relationships between MEG-
variables (task and resting- state) and GABA/Glutam-
ate levels with psychopathological variables
(CAARMS, SPI-A) and neuropsychology (BACS) in
the CHR-group. Specifically, we will identify those
MEG (sensor, frequency and source-regions) and
MRS-parameters with the largest effect size and per-
form information theoretical analysis to identify linear
and non-linear dependencies.
In addition to parametric analysis of group differences
in baseline-variables, we will employ a multivariate ma-
chine learning technique towards the development of
predictors for conversions and functional outcome in
CHR-individuals, an approach which has been used re-
cently in the neuroanatomical classification of ScZ [72].
In the first step, we will reduce the dimensionality of the
MEG-data by focusing on reconstructed source-time
courses with significant task effects (baseline vs. task).
For resting-state data, we will employ a principal com-
ponent analysis (PCA) to the source-reconstructed activ-
ity in the 4–200 Hz frequency range in order to reduce
the number of variables.
To examine transitions, we employ a Generalized Lin-
ear Model (GLM) to assign MEG-data of individual sub-
jects to one of the three designated categories (controls
vs. transitioned CHR vs. non-transitioned CHR). Follow-
ing a 10-fold cross validation, we will divide the total
sample into 10 non-overlapping samples. Each sample
will be iteratively held back as test data while the classi-
fier is trained on the 9 remaining samples. A multiclass
logistic regression (GLM) ranks features by their esti-
mated effect on the resulting model’s performance. A
general ranking scheme will combine the results ob-
tained from 10 iterations. A subset of 3 to 10 top rank-
ing signal features will be re-evaluated and the
combination of features resulting in the best classifica-
tion performance will serve as the diagnostic MEG-
index.
Discussions
Evidence has accumulated that the onset of severe men-
tal health problems in adolescence, such as psychosis, is
preceded by alterations in functional and anatomical
brain networks [71, 72] as well as with changes in psy-
chological processes related to affect regulation [26].
Accordingly, further insights into the neurobiological as
well as psychosocial factors that confer risk and resili-
ence towards the development of psychosis and poor
functional outcomes in CHR-individuals is an important
objective.
We expect that the YouR-study will provide novel
data to address these questions as well yield bio-
markers that allow prediction of mental health out-
comes in CHR-individuals. Specifically, we expect for
the first-time a comprehensive characterization of the
role of neural oscillations in emerging psychosis and
its relationship to changes in E/I-balance parameters.
While both rhythmic activity and alterations in
GABA/Glutamatergic neurotransmission have been
implicated in circuit abnormalities and cognitive defi-
cits in established ScZ [15], their role in the early
stages of psychosis is less clear. Accordingly, these
data could inform novel approaches towards the at-
risk mental state paradigm as well as allow the search
for targeted approaches to correct abnormalities in
circuit dysfunctions which could eventually lead to
the prevention of severe mental health outcomes dur-
ing the transition from adolescence to adulthood.
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